Our nanoimmunotherapy solution
ImmunoBlue harnesses the advantages of nanomedicine and immunotherapy for treating advanced cancers. ImmunoBlue has developed a nanoparticle platform composed of an FDA-approved material, which when laser-activated to a tumor-specific immunogenic thermal dose “window” discovered by us, generates potent responses from the immune system to more effectively treat advanced cancers. These effects combine synergistically with monoclonal antibodies to generate long-term survival and immunological memory in various cancer models (e.g. melanoma, neuroblastoma).
Our technology is:
Safe: Composed of an FDA-approved and biodegradable material
Specific: Used at a proprietary tumor-specific thermal dose window
Synergistic: Combines with mAbs to generate long-term survival and durable immunological memory
Scalable: Manufactured at scale for IND-enabling tox studies